E-Mail
IMAGE: Three receptor tyrosine kinases (RTKs) EGFR (orange), HER2 (pink), and MET (green) are imaged before and after the use of a MET-selective tyrosine kinase inhibitor (Trametinib), and trametinib, a mitogen activated protein. view more
Credit: Image created by Patricia Pereira, PhD, Research Associate at Memorial Sloan Kettering Cancer Center
Reston, VA Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer. The new research was published in the March issue of The
Journal of Nuclear Medicine.
The research showed that immuno-PET successfully visualizes changes in different cancer receptors (receptor tyrosine kinases, or RTKs) within tumors during targeted therapies. This gives physicians a tool that can be used to evaluate the effectiveness of a treatment soon after its administration.